Wang, J. (2013). Bringing cancer serological diagnosis to a new level. Future Oncology. Available online at http://www.medscape.com/viewarticle/776799_3. Accessed Jan 2018.

(October 2013) Wolff A, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Journal of Clinical Oncology. Available online at http://ascopubs.org/doi/abs/10.1200/JCO.2013.50.9984?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed. Accessed Jan 2018.

Perez, E.A. et al (2014 November). Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2–positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal of Clinical Oncology. Available online at http://ascopubs.org/doi/full/10.1200/JCO.2014.55.5730. Accessed Jan 2018.

Poznak, C.V. (2015 August). Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. Available online at http://ascopubs.org/doi/full/10.1200/jco.2015.61.1459. Accessed Jan 2018.

Markman, M. (2018 Jan 15). Breast Cancer and HER2, Overview of HER2 breast cancer. Medscape. Available online at http://emedicine.medscape.com/article/1689966-overview. Accessed Jan 2018.

(© 2016). National Breast Cancer Foundation. Lab Tests. Available online at http://www.nationalbreastcancer.org/breast-cancer-lab-tests. Accessed Jan 2018.

Harris, L. et al. (2016 April). Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-state invasive breast cancer: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology. Available online at http://ascopubs.org/doi/pdf/10.1200/jco.2015.65.2289. Accessed Jan 2018.

(Reviewed 2016 June 1). Breast cancer HER2 status. American Cancer Society. Available online at https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html. Accessed Jan 2018.

Denduluri, N. et al. (2016 July). Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. Journal of Clinical Oncology. Available online at http://ascopubs.org/doi/full/10.1200/JCO.2016.67.0182. Accessed Jan 2018.

Reix, N. (2016 October 5). A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression. Available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065601/. Accessed Jan 2018.

(Reviewed 2017 April) HER2/neu testing. Quest Diagnostics. Available online at http://www.questdiagnostics.com/testcenter/testguide.action?dc=CF_HER_2. Accessed Jan 2018.

Chalsasani, P. (Updated 2017 June 27). Breast cancer workup. Medscape. Available online at http://emedicine.medscape.com/article/1947145-workup#aw2aab6b5b6. Accessed Jan 2018.

Factor, R. E. (Updated 2017 July). Breast cancer. Arup Consult. Available online at https://arupconsult.com/content/breast-cancer/?tab=tab_item-6. Accessed Jan 2018.

American Cancer Society. Targeted Therapy for Breast Cancer. Available online at https://www.cancer.org/cancer/breast-cancer/treatment/targeted-therapy-for-breast-cancer.php. Accessed Jan 2018.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr; American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 Nov 20;25(33):5287-312.

Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015 Aug 20;33(24):2695-704. doi: 10.1200/JCO.2015.61.1459.

Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, Hammond EH, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Bast RC, Hayes DF; American Society of Clinical Oncology. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Apr 1;34(10):1134-50. doi: 10.1200/JCO.2015.65.2289.

Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012 Aug;1826(1):199-208. doi: 10.1016/j.bbcan.2012.03.012.

Tsé C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev. 2012 Apr;38(2):133-42. doi: 10.1016/j.ctrv.2011.03.008.

Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer. Clin Chim Acta. 2015 Feb 2;440:16-22. doi: 10.1016/j.cca.2014.11.001.

Lee SB, Lee JW, Yu JH, Ko BS, Kim HJ, Son BH, Gong G, Lee HJ, Kim SB, Jung KH, Ahn JH, Lee W, Sung J, Ahn SH. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer. BMC Cancer. 2014 Dec 10;14:929. doi: 10.1186/1471-2407-14-929.

Mishra R, Hanker AB, Garrett JT. Genomic alterations of ERBB receptors in cancer: clinical implications. Oncotarget. 2017 Nov 30;8(69):114371-114392. doi: 10.18632/oncotarget.22825.

Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Arch Pathol Lab Med. 2016 Dec;140(12):1345-1363.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014 Feb;138(2):241-56. doi: 10.5858/arpa.2013-0953-SA.

NCCN Guidelines for Patients, Breast Cancer, Early Stage, Version 1.2016. Available online at https://www.nccn.org/patients/guidelines/stage_i_ii_breast/files/assets/basic-html/page-1.html. Accessed June 2018.

NCCN Guidelines for Patients, Stomach Cancer, Version 1.2016. Available online at https://www.nccn.org/patients/guidelines/cancers.aspx#stomach. Accessed June 2018.

Thomas, Clayton L., Editor (1997). Taber's Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby's Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

Check, W. (2002 February). Making the call on HER2 testing methods. CAP Today, In the News [On-line journal]. Available online at http://www.cap.org/html/publications/feature.html.

Check, W. (2002 February). Serum HER2 testing. CAP Today, In the News [On-line journal]. Available online at http://www.cap.org/html/publications/sidebar1.html.

ASCO (1996). c-erbB-2 as a Marker for Breast Cancer. American Society for Clinical Oncology [On-line guideline]. Available online at http://www.asco.org/prof/pp/html/guide/tumor/m_tumor14.htm.

ACS (2001). Immunotherapy with Trastuzumab (Herceptin). American Cancer Society [On-line information]. Available online through http://www.cancer.org.

ACS (2001). How is Breast Cancer Diagnosed? American Cancer Society, Cancer Reference Information [On-line information]. Available online through http://www.cancer.org.

Locke, J. (2001 February). HER2/neu Testing. American Association for Clinical Chemistry, Strategies [Newsletter]. Available through AACC (http://www.aacc.org)

Yazifi, H., and Gown, A. (2002 June). Controversies and guidelines in tissue-based HER-2/neu testing in breast cancer. Medical Laboratory Observer [Journal], Vol. 34 (6), pp 12-16,20. Available through MLO (http://www.mlo-online.com)

MEDCEU (1999). Breast Cancer and HER2. MEDCEU [On-line continuing education]. Available online at http://www.medceu.com/course-no-test.cfm?CID=307.

Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 200-202.

Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 548-551.

Hicks, D. and Kulkarni, S. (2008 April 14). HER2+ Breast Cancer: Review of Biologic Relevance and Optimal Use of Diagnostic Tools. Medscape from American Journal of Clinical Pathology [On-line information]. Available online at http://www.medscape.com/viewarticle/570732. Accessed July 2009.

Markman, M. (2009 June 30, Updated). Breast Cancer and HER2. Emedicine [On-line information]. Available online at http://emedicine.medscape.com/article/1689966-overview. Accessed July 2009.

(2009 May, Updated). Breast Cancer Management Assays. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/OncologicDz/GynecologicalTumors/BreastCancerManagement.html#. Accessed July 2009.

(2008 December 02). NCCN Clinical Practice Guidelines in Oncology, Breast Cancer v.1.2009 Medscape from National Comprehensive Cancer Network [On-line information]. PDF available for download at http://misc.medscape.com/images/586/406/Breast-Medscape.pdf. Accessed July 2009.

(2006 December). What to Know: ASCO's Guideline on HER2 Testing for Breast Cancer. American Society of Clinical Oncologists [On-line information]. Available online through http://www.cancer.net. Accessed July 2009.

Esteva, F. et. al. (2005 May 13). Clinical Utility of Serum HER2/neu in Monitoring and Prediction of Progression-Free Survival in Metastatic Breast Cancer Patients Treated With Trastuzumab-Based Therapies. Medscape from Breast Cancer Research [On-line information]. Available online at http://www.medscape.com/viewarticle/503103. Accessed July 2009.

Tse, C. et. al. (2005). Evaluation of the Quantitative Analytical Methods Real-Time PCR for HER-2 Gene Quantification and ELISA of Serum HER-2 Protein and Comparison with Fluorescence in Situ Hybridization and Immunohistochemistry for Determining HER-2 Status in Breast Cancer Patients. Clinical Chemistry. 2005;51:1093-1101 [On-line information]. Available online at http://www.clinchem.org/cgi/reprint/51/7/1093. Accessed July 2009.

Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005 Sep 5;93(5):552-6.

Lower EE, Glass E, Blau R, Harman S. HER-2/neu expression in primary and metastatic breast cancer. 1: Breast Cancer Res Treat. 2009 Jan;113(2):301-6. Epub 2008 Feb 14.

Carney WP, Brown-Shimer S, Hamer PJ. Serum HER-2/neu testing can identify HER-2/neu positive patients previously classified as negative by tissue testing. American Association for Clinical Chemistry Annual Meeting Proceedings, 2008. Clin Chem Vol 54(56) Suppl, Pg A130: Abstract No. C-96.

Schwartz MK, et al. International Journal of Biological Markers 2000;15(4):324.

Lipton A, et al. Journal of Clinical Oncology 2002;20(6):1467.

Esteva FJ, et al. Journal of Clinical Oncology 2002;20(7):1800.

Lipton et al. Serial Serum HER2/neu Levels and Clinical Response Status for Study EGF20009 - Metastatic Breast Cancer, Sept 7th 2007, ASCO Breast Cancer Meeting, San Francisco.

Serum HER-2/neu and Relative Resistance to TRASTUZUMAB-based Therapy in Patients With Metastatic Breast Cancer. Cancer 2008; 113:1294-1301.

(Updated July 2013). Breast Cancer Workup. Medscape reference. Available online at http://emedicine.medscape.com/article/1947145-workup#aw2aab6b5b6. Accessed July 2013.

Ithimakin, Suthinee et al. HER2 Drives Luminal Breast Cancer Stem Cells in the Absence of HER2 Amplification: Implications for Efficacy of Adjuvant Trastuzumab. Cancer Research. February 2013. Available online at http://cancerres.aacrjournals.org/content/early/2013/02/14/0008-5472.CAN-12-3349.abstract. doi: 10.1158/0008-5472.CAN-12-3349 Accessed July 2013.

(Copyright 2012). Breast Cancer and Breast Pathology. John Hopkins University. Available online at http://pathology.jhu.edu/breast/biomarker-testing.php. Accessed July 2013.

(Updated December 2012) HER2/neu Testing. Quest Diagnostics. Available online at http://www.questdiagnostics.com/testcenter/testguide.action?dc=CF_HER_2. Accessed July 2013.

Markman, M. (2013 February 13, Updated). Breast Cancer and HER2. Emedicine [On-line information]. Available online at http://emedicine.medscape.com/article/1689966-overview. Accessed July 2013.

Breast Cancer Management Assays. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/Breastcancer.php. Accessed July 2013.

(Updated 2013). HER2 Testing: Summary for Breast Cancer Patients. Available online at http://www.nccn.com/about-us/61-symptoms-category.html. Accessed July 2013.

(©2012). What to Know: ASCO's Guideline on HER2 Testing for Breast Cancer. American Society of Clinical Oncologists. Available online at http://www.cancer.net/publications-and-resources/what-know-ascos-guidelines/what-know-ascos-guideline-her2-testing-breast-cancer. Accessed July 2013.

(Updated June 2011). Serum HER2 Testing. Atlantic Health System. Available online at https://atlantichealth.dnadirect.com/grc/patient-site/her2-serum/index.php. Accessed July 2013.

(November 2008) ARUP Laboratories Technical Bulleting. HER-2/neu Serum For monitoring soluble HER-2/neu protein in patients with metastatic breast cancer. Available online at http://www.aruplab.com/Testing-Information/resources/TechnicalBulletins/HER-2neu%20Serum.pdf. Accessed August 2013.

Carney W, et al. Potential Clinical Utility of Serum HER-2/neu Oncoprotein Concentrations in Patients with Breast Cancer. Clinical Chemistry, October 2003 vol. 49 no. 10 1579-1598. Available online at http://www.clinchem.org/content/49/10/1579.short. Accessed August 2013.

(October 2013) Wolff A, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. Available online at http://www.asco.org/quality-guidelines/recommendations-human-epidermal-growth-factor-receptor-2-testing-breast-cancer. Accessed October 2013.

Lam L, et al. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim Biophys Acta. 2012 August; 1826(1): 199–208. Available online at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362659/. Accessed October 2013.

Gregory J. Tsongalis, PhD, HCLD, CC, Professor of Pathology, Director, Molecular Pathology, Dartmouth Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, NH.